FDA Approves Dendreon's Atlanta Cancer Immunotherapy Manufacturing Facility

Dendreon Corporation DNDN today announced that the U.S. Food and Drug Administration approved its Atlanta cancer immunotherapy manufacturing facility, the third location at which the Company will produce PROVENGE® to help meet the needs of patients across the U.S. with asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer. The Atlanta facility includes 36 workstations, and Dendreon will bring these new workstations online in a staged approach. With this FDA approval and the approved New Jersey and Los Angeles facilities, Dendreon now has three facilities available to manufacture PROVENGE.